Winfield Associates’s Haemonetics HAE Stock Holding History

Winfield Associates’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-97	Closed	-$4K	–	831
2017 Q2	$4K	Buy	+97	New	+$3.98K	﹤0.01%	571

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Winfield Associates's HAE Position: Q3 2017 in Review

Winfield Associates sold out of Haemonetics (HAE) in Q3 2017, closing a stake of 97 shares — an estimated $4K sold.

Winfield Associates first reported a position in HAE in Q2 2017 and held it in 1 quarter. The position peaked at $4K in Q2 2017. 207 funds tracked by Wall St. Rank hold HAE as of Q3 2017.

Winfield Associates reported no remaining Haemonetics position as of Q3 2017 after selling out during the quarter.
Winfield Associates sold 97 Haemonetics shares in Q3 2017, an estimated $4K.
Winfield Associates first reported a position in Haemonetics in Q2 2017 and held it in 1 quarter.
Winfield Associates's Haemonetics position peaked at $4K in Q2 2017.
207 funds tracked by Wall St. Rank held Haemonetics as of Q3 2017.

Based on Winfield Associates's 13F filing for Q3 2017, filed 6 Nov 2017.